Copyright ©The Author(s) 2021.
World J Hepatol. Jun 27, 2021; 13(6): 662-672
Published online Jun 27, 2021. doi: 10.4254/wjh.v13.i6.662
Figure 1
Figure 1 Oncoprint of genetic alterations and mRNA elevations. The alterations to the 12 genes identified by the amplification driver gene identification strategy were visualized using the cBioPortal Oncoprint tool. The nature of the alterations is indicated by the key below the Oncoprint. Note that some individuals display both amplification (solid red) plus elevated mRNA (red outline). Each vertical set of lines reflects the alterations occurring in a single hepatocellular carcinoma patient. Individuals with no alterations detected in any of the 12 genes are not shown.
Figure 2
Figure 2 Frequency of TPM3 or NUF2 alterations in other cancers. Analyses from cBioPortal show the percent of cancer cases that include a TPM3 gene alteration (upper plot) or a NUF2 gene alteration. The results were generated by first selecting all 32 of The Cancer Genome Atlas PanCancer Atlas studies[41] from the cBioPortal Query page, and then searching for DNA alterations in the TPM3 gene and NUF2 gene individually. Graphs shown in this figure were taken from the Cancer Types Summary results page that is produced by cBioPortal following this search. The colors above represent the following: green, mutation; purple, fusion; red, amplification; blue, deep deletion; grey, multiple alterations.